
Natco Pharma Q3 net surges to ₹213 cr. on higher revenue
The Hindu
Natco Pharma's net profit for Q3 surged to ₹212.7 crore, driven by a 55% increase in total income.
Natco Pharma reported consolidated net profit for quarter ended December surged to ₹.212.7 crore from ₹62.3 crore in the year-earlier period on the back of a 55% increase in total income.
However, both net profit and total income on a sequential basis were lower. For the September quarter, the drugmaker had posted ₹369 crore in net profit on a total revenue of ₹1,060.8 crore.
The increase in total revenue, year-on-year, for the third quarter to ₹795.6 crore (₹513.3 crore) was driven primarily by higher formulations exports at ₹605.6 crore (₹333.7 crore). Revenue from domestic formulations declined to ₹99.4 crore (₹101.1 crore), while APIs contribution was marginally better at ₹46.3 (₹42.6 crore).
Natco Pharma said the company has shown strong growth across businesses compared to last year and is confident of its strategy going forward. It has declared an interim dividend of ₹1.25 per equity share. On Wednesday, shares of the company ended 3.10% higher at ₹883.85 apiece on the BSE.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












